APPLICATION
NDA020075
TYPE
NDA
ORIGINAL APPROVAL
1992-06-17
LATEST ACTION
2021-12-13
ROUTE
INTRATHECAL
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Prescription
Products
LIORESAL · ReferencePrescription
BACLOFEN 0.05MG/ML · INJECTABLE · INTRATHECAL
LIORESAL · ReferencePrescription
BACLOFEN 0.5MG/ML · INJECTABLE · INTRATHECAL
LIORESAL · ReferencePrescription
BACLOFEN 2MG/ML · INJECTABLE · INTRATHECAL
Approval history
2016-12-22Manufacturing (CMC) · Supplement 33 · standardAP
2016-06-07Manufacturing (CMC) · Supplement 29 · priorityAP
2014-06-05Manufacturing (CMC) · Supplement 30 · priorityAP
2013-09-05Manufacturing (CMC) · Supplement 27 · priorityAP
2013-01-10Manufacturing (CMC) · Supplement 25 · priorityAP
2002-12-10Manufacturing (CMC) · Supplement 18 · priorityAP
2001-05-03Manufacturing (CMC) · Supplement 15 · priorityAP
2000-03-03Manufacturing (CMC) · Supplement 6 · priorityAP
1999-05-05Manufacturing (CMC) · Supplement 12 · priorityAP
1998-08-21Manufacturing (CMC) · Supplement 9 · priorityAP
1998-08-21Manufacturing (CMC) · Supplement 8 · priorityAP
1998-06-23Manufacturing (CMC) · Supplement 7 · priorityAP
1996-11-07Manufacturing (CMC) · Supplement 5 · priorityAP
1996-06-14Efficacy · Supplement 4 · standardAP
1994-05-20Manufacturing (CMC) · Supplement 2 · priorityAP
1992-06-17Type 3 - New Dosage Form · Original · priorityAP
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.